Skip to main content
Premium Trial:

Request an Annual Quote

Researchers Sequence Strain of H. Influenzae That Causes Ear Infections

NEW YORK, Aug. 18 (GenomeWeb News) - A multi-state group of researchers has sequenced the genome of a pathogenic strain of nontypeable Haemophilus influenzae, one of the scientists said yesterday.


Performing the sequencing were researchers from the Columbus Children's Research Institute, Ohio State University College of Medicine and Public Health, and the University of Oklahoma Health Sciences Center.


The pathogen causes pediatric ear infections and diseases of the respiratory tract and is the number one reason young children are seen by pediatricians.


The researchers hope that the genome sequence, which was published in the July issue of the Journal of Bacteriology, will help them design a vaccine or novel intervention strategies for ear infections.


Ten years ago, H. influenzae was the first bacterial genome sequenced by a shotgun strategy. However, that particular strain did not cause ear infections.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.